Genetic identification of familial hypercholesterolemia within whole genome sequences in 6820 newborns
Clinical Genetics · 2024
DOI: 10.1111/cge.14453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2024. Verfasst von Yingchao Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genetic Testing center, Qingdao Women and Children's Hospital, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Qingdao Natural Science Foundation, Qingdao Science and Technology Plan.
Abstract (Originalsprache)
Familial hypercholesterolemia (FH) is defined as a monogenic disease, characterized by elevated low‐density lipoprotein cholesterol (LDL‐C) levels. FH remains underdiagnosed and undertreated in Chinese. We whole‐genome sequenced 6820 newborns from Qingdao of China to investigate the FH‐related gene ( LDLR , APOB , PCSK9 ) mutation types, carrier ratio and genotype–phenotype correlation. In this study, the prevalence of FH in Qingdao of China was 0.47% (95% CI: 0.32%–0.66%). The plasma lipid levels of FH‐related gene mutation carriers begin to increase as early as infant. T‐CHO and LDL‐C of FH infants was higher by 48.1% ( p < 0.001) and 42.9% ( p < 0.001) relative to non‐FH infants. A total of 22 FH infants and their parent participate in further studies. The results indicated that FH infant parent noncarriers have the normal plasma lipid level, while T‐CHO and LDL‐C increased in FH infants and FH infant parent carriers, but no difference between the groups. This highlights the importance of genetic factors. In conclusion, the spectrum of FH‐causing mutations in the newborns of Qingdao, China was described for the first time. These data can serve as a considerable dataset for next‐generation sequencing analysis of the Chinese population with FH and potentially helping reform regional policies for early detection and prevention of FH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genetic Testing center, Qingdao Women and Children's Hospital, Qingdao University, Qingdao, China.
- Heart Center, Qingdao Women and Children's Hospital, Qingdao University, Qingdao, China.
- Fetal Medicine Center, Qingdao Women and Children's Hospital, Qingdao University, Qingdao, China.
Förderung
- National Natural Science Foundation of China
- Qingdao Natural Science Foundation
- Qingdao Science and Technology Plan
- Taishan Scholars Program of Shandong Province
- Natural Science Foundation of Qingdao Municipality
Zitieren
APA
Zhou, Y., Luo, G., Zhang, A., Gao, S., Tang, Y., Du, Z., & Pan, S. (2024). Genetic identification of familial hypercholesterolemia within whole genome sequences in 6820 newborns. Clinical Genetics. https://doi.org/10.1111/cge.14453
Vancouver
Zhou Y, Luo G, Zhang A, Gao S, Tang Y, Du Z, et al. Genetic identification of familial hypercholesterolemia within whole genome sequences in 6820 newborns. Clinical Genetics. 2024. doi:10.1111/cge.14453
BibTeX
@article{Zhou2024,
author = {Zhou, Yingchao and Luo, Gang and Zhang, Ai and Gao, Shuai and Tang, Yaqi and Du, Zhanhui and Pan, Silin},
title = {Genetic identification of familial hypercholesterolemia within whole genome sequences in 6820 newborns},
journal = {Clinical Genetics},
year = {2024},
doi = {10.1111/cge.14453}
}
EUVIMED